6761 - 6770 of 8620 Results
Title
Year
- The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease2019RESTRICTEDTitle: The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson DiseaseJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 77Issue #: 3Start Page: 295End Page: 295Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2019.3983Citation Count: 13
-
OPENTitle: Freezing of Gait and Its Levodopa ParadoxJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 77Issue #: 3Start Page: 287End Page: 287Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2019.4006Best OA location URL: https://jamanetwork.com/journals/jamaneurology/articlepdf/2757501/jamaneurology_nonnekes_2019_vp_190017.pdfCitation Count: 49
- Seven-Year Experience From the National Institute of Neurological Disorders and Stroke–Supported Network for Excellence in Neuroscience Clinical Trials2020OPENTitle: Seven-Year Experience From the National Institute of Neurological Disorders and Stroke–Supported Network for Excellence in Neuroscience Clinical TrialsJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 77Issue #: 6Start Page: 755End Page: 755Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2020.0367Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7483960Citation Count: 8
- Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson’s disease.2019OPENTitle: Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson’s disease.Journal Name: NeuropsychologyPublisher: American Psychological Association (APA)Vol: 34Issue #: 1Start Page: 24End Page: 30Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.1037/neu0000577Best OA location URL: http://psycnet.apa.org/journals/neu/34/1/24.pdfCitation Count: 20
- Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients2020OPENTitle: Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic PatientsJournal Name: JAMA OncologyPublisher: American Medical Association (AMA)Vol: 6Issue #: 5Start Page: 714End Page: 714Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1001/jamaoncol.2020.0001Best OA location URL: https://jamanetwork.com/journals/jamaoncology/articlepdf/2761984/jamaoncology_fehlmann_2020_oi_200001.pdfCitation Count: 115
-
OPENTitle: Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network HubsJournal Name: The Journal of Neuropsychiatry and Clinical NeurosciencesPublisher: American Psychiatric Association PublishingVol: 32Issue #: 4Start Page: 370End Page: 375Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1176/appi.neuropsych.19070165Best OA location URL: https://neuro.psychiatryonline.org/doi/pdf/10.1176/appi.neuropsych.19070165Citation Count: 24
- Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study2020OPENTitle: Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' studyJournal Name: BMJ OpenPublisher: BMJVol: 10Issue #: 8Start Page: e038911End Page: e038911Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1136/bmjopen-2020-038911Best OA location URL: https://bmjopen.bmj.com/content/bmjopen/10/8/e038911.full.pdfCitation Count: 28
- The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question—are polyphenols a viable therapeutic option against proteinopathies?2020OPENTitle: The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question—are polyphenols a viable therapeutic option against proteinopathies?Journal Name: Annals of Translational MedicinePublisher: AME Publishing CompanyVol: 8Issue #: 11Start Page: 719End Page: 719Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.21037/atm.2020.01.117Best OA location URL: https://atm.amegroups.com/article/viewFile/35635/pdfCitation Count: 7
- Patient and caregiver characteristics associated with caregiver burden in Parkinson’s disease: a palliative care approach2019OPENTitle: Patient and caregiver characteristics associated with caregiver burden in Parkinson’s disease: a palliative care approachJournal Name: Annals of Palliative MedicinePublisher: AME Publishing CompanyVol: 9Issue #: S1Start Page: S24End Page: S33Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.21037/apm.2019.10.01Best OA location URL: https://apm.amegroups.com/article/viewFile/31642/26522Citation Count: 130
-
OPENTitle: Investigating lymphocyte populations in patients with Parkinson’s diseaseJournal Name: Annals of Translational MedicinePublisher: AME Publishing CompanyVol: 8Issue #: 6Start Page: 276End Page: 276Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.21037/atm.2020.02.29Best OA location URL: https://atm.amegroups.com/article/viewFile/37712/pdfCitation Count: 3